Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)

Matulonis, Ursula

132 - Focused Plenary
Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)

Monday, March 24, 2014: 3:50 PM

Ballroom B/C (Tampa Convention Center)

U. A. Matulonis¹, P. Harter², C. Gourley³, M. Friedlander⁴, I. B. Vergote⁵, G. J. S. Rustin⁶, A. Fielding⁷, S. Spencer⁷, T. W. Ho⁸ and J. A. Ledermann⁹
¹Dana-Farber Cancer Institute, Boston, MA, ²Kliniken Essen-Mitte, Essen, Germany, ³University of Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom, ⁴Prince of Wales Hospital, Randwick, Australia, ⁵University Hospital Leuven, Leuven, Belgium, ⁶Mount Vernon Hospital, Middlesex, United Kingdom, ⁷AstraZeneca, Macclesfield, United Kingdom, ⁸AstraZeneca, Wilmington, DE, ⁹University College London, London, United Kingdom

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

132 - Focused Plenary
Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)

132 - Focused Plenary Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)

132 - Focused Plenary
Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)